Ventricular Remodeling After Infarction and the Extracellular Collagen Matrix
When Is Enough Enough?
Bodh I. Jugdutt, MD L eft ventricular (LV) remodeling after myocardial infarction (MI) contributes significantly to LV dilation and dysfunction, and disability and death. Two paradigms, pertinent to antiremodeling therapy after MI (Figure 1) , have evolved over the last 3 decades. Paradigm 1, LV remodeling is a major mechanism for disability and death, 1,2 has received a great deal of attention. In contrast, paradigm 2, remodeling of the extracellular collagen matrix (ECCM) plays a major role in LV remodeling, [3] [4] [5] [6] [7] whereby decrease, disruption, and/or defective composition of the ECCM promote LV dilation and rupture, 4 -7 has received little attention. A host of clinical trials showed that angiotensin-converting enzyme (ACE) inhibitors (ACE-Is) with or without aldosterone antagonists, angiotensin II (AngII) type 1 (AT 1 ) receptor blockers (ARBs), ␤-adrenergic blockers or reperfusion improve outcome in survivors of MI. 8 -10 Concurrent evidence has underscored the importance of preserving the ECCM during healing after MI. [2] [3] [4] [5] [6] [7] However, the antifibrotic action of ACE-Is, aldosterone antagonists and ARBs on ECCM in the infarct zone (IZ) and noninfarct zone (NIZ), 6, 7, 9, 11 and the reperfusion-induced damage to the ECCM in the IZ, 5, 7, 12 remain unreconciled with the benefits. 8 -10,13 Nevertheless, excessive ECCM, as in dilated ischemic cardiomyopathy after remote MI, 14, 15 can contribute to LV diastolic dysfunction and poor outcome, 6 suggesting that antifibrotic drugs that target excess ECCM might be a logical therapeutic approach. This review focuses on the role of the ECCM in the evolution of LV remodeling after MI and the potential impact of therapies that target the ECCM.
Ventricular Remodeling After MI and the Role of ECCM
Five points merit emphasis. First, the LV remodeling process after MI is complex, dynamic, and time dependent, and progresses in parallel with healing over months. 1, 2, 7, 16 Notably, it involves differential changes between the IZ and NIZ with respect to the following: (1) LV structure, shape, and topography 1,2 ( Figure 1) ; (2) cell type, such as myocytes and nonmyocytes (Table 1) 6, 7, [17] [18] [19] [20] [21] [22] [23] ; (3) proteins, cytokines, and growth factors 7, 24, 25 ; and (4) the ECCM. 5-7,13-17,19 -23 Differential regional remodeling of the ECCM contributes significantly to global LV structural remodeling after MI (Figure 2 ) 7,9,26 and plays a pivotal role in paradigm 1. 3, 6, 7 Second, the post-MI heart shows remarkable capacity to adapt to the rather sudden development of an IZ and a NIZ. Thus, MI results in time-dependent damage to myocytes, nonmyocytes, and the ECCM in the IZ; ventricular dysfunction followed by volume overload and progressive dilation; reactive hypertrophy with interstitial fibrosis and increased collagen in the NIZ; gradual reparative fibrosis in the IZ 27 ; and vascular remodeling in the IZ and NIZ. 7 Third, several endogenous molecules that affect collagen synthesis and are upregulated after MI, and several agents that are used therapeutically for MI, affect collagen turnover (Table 2, Figure 3 ) and exert an antifibrotic effect. 2, 7, 9, 10, 28 This can potentially alter ECCM remodeling in the IZ 9,28 and impair healing, 29 and thereby promote adverse remodeling and outcome, depending on their timing relative to pathophysiological stages of healing (Table 3) .
Fourth, a fine balance, between matrix metalloproteinases (MMPs) that degrade ECCM and endogenous tissue inhibitors of MMPs (TIMPs) that inhibit MMPs, 30 -32 maintains normal remodeling and function, and an imbalance can result in adverse remodeling. 24, 25, 30, 33, 34 Fifth, although a 2-to 3-fold increase in myocardial collagen above the normal level results in increased LV stiffness and mild dysfunction, 35 a very small decrease in collagen below normal can lead to drastic consequences, 36, 37 including LV dilation 4, 22, 34 and rupture. 33, 38 In reperfused MI, decreased or damaged ECCM in the IZ 5, 12, 39 is associated with cardiac rupture. 5, 39 Key Points to Remember About Pathobiology of Cardiac ECCM First, nearly 75% of the cells in the healthy heart are nonmyocytes, which include fibroblasts 18, 21 that account for 90% to 95% of nonmyocyte cell mass 17, 20, 21 (Table 1) . Myocardial cells are supported by a matrix (Table 4) consisting of a macromolecular network of fibers 36 with intricate 3D organization 11 that largely determines the structural and functional integrity of the heart. 7 Second, fibroblasts and myofibroblasts (myoFbs) 18 produce most of the matrix macromolecules, including collagen, the principal structural protein. 36, 40 Third, the collagen molecules consist of a central core of long, stiff, triple-stranded helices in which 3 ␣ chains wind around each other to form a superhelix. 40 Of the many collagen types (Table 5) , the major fibrillar collagens are types I and III, which constitute the bulk of cardiac ECCM. 20 Thus, Ϸ85% of total collagen is type I, 40 which is associated mainly with thick fibers that confer tensile strength and resistance to stretch and deformation, whereas Ϸ11% of total collagen is type III, 40 which is associated with thin fibers that confer resilience. The other matrix components also mediate important functions (Table  4) . 40, 41 Fourth, collagen biosynthesis involves Ϸ8 enzymatic steps, including intracellular synthesis of pro-␣ chains, hydroxylation, glycosylation, formation of procollagen triple helixes, secretion into extracellular space, conversion into less soluble molecules, assembly into fibrils, and aggregation into fibers. 7, 36, 40 The key enzyme, prolyl-4-hydroxylase (P4H), catalyzes the hydroxylation of proline on ␣ monomers to yield stable protocollagen molecules that are secreted into the ECCM. P4H requires several cofactors, including ascorbic acid (vitamin C). 36, 40 Other factors also influence collagen synthesis 7 and include growth factors, such as transforming growth factor-␤ 1 (TGF-␤ 1 ), insulin growth factor and connective tissue growth factor (CTGF), cytokines such as tumor necrosis factor-␣ (TNF-␣) and interleukin-1 (IL-1), and various hormones and enzymes (Table 2, Figure 3) .
Fifth, the orderly degradation of ECCM, critical for growth, remodeling and repair, 36, 40 is mediated mainly by MMPs (Table 5) . 30, 31 The collagenases (MMP-1, -8, and -13) are highly specific and primarily cleave fibrillar collagens at specific sites, thereby destroying structural integrity with the minimum amount of proteolysis. The gelatinases (MMP-2 and -9) degrade the denatured fibrillar collagens, other collagen types, and elastins. 42 Once MMPs bind to collagen fibrils and begin their attack, they could continue to act until all collagen is degraded unless they are inhibited by the TIMPs, which provide an essential inhibitory mechanism against uncontrolled degradation by MMPs. 40, 42 Sixth, the net proteolytic activity of MMPs depends on their transcription, activation, and inhibition. 7 Transcription from MMP genes to pro-MMPs is stimulated by several factors including IL-1, platelet-derived growth factor (PDGF), and TNF-␣, and inhibited by others, including TGF-␤, retinoids, heparin, and corticosteroids. Activation of latent pro-MMPs to active MMPs is stimulated largely by the urokinase plasminogen activator (uPA)/plasmin system, expressed in several cells including monocytes and macrophages, and inhibited by TIMPs. The uPA system, with its specific receptor uPAr and its inhibitors plasminogen activator inhibitor [PAI] 1 and 2, localizes the proteolytic activity. Inhibition of activated MMPs by TIMPs and drugs, such as tetracyclines, anthracyclines, synthetic TIMP inhibitors, regulate the proteolysis of ECCM.
Seventh, myocardial MMPs and TIMPs are coexpressed and secreted by several cell types including fibroblasts, endothelial cells, and inflammatory cells, and their gene expression is tightly controlled at the transcription level. 32 Several cytokines, polypeptide growth factors, hormones, steroids, and phorbol esters modulate the synthesis and secretion of pro-MMPs and TIMPs. The fibrotic effect of TGF-␤ 1 may be due not only to stimulation of ECCM formation but also to decreased MMP and increased TIMP levels 7 or to a decreased MMP/TIMP ratio.
Eighth, chronic LV pressure overload, leading to concentric hypertrophy, is associated with increased ECCM 6 and LV diastolic dysfunction, 35 thus providing the basis for antifibrotic therapy. Chronic LV volume overload, leading to eccentric hypertrophy, is associated with increased ECCM, 7, 43 collagen cross-linking, 43 and fibronectin. 7 In human end-stage heart failure from ischemic cardiomyopathy, collagen, 14 cytoskeletal proteins, 7 and CTGF 7 are increased, but collagen cross-links are decreased, 11 thus favoring LV dilation. 7 In human end-stage 
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Ventricular Remodeling Postinfarction and the ECCMMI, total collagen and the type I/III ratio are increased in the IZ scar and border areas but not in the NIZ, 15 suggesting that the NIZ remains susceptible to dilation. Thus, antifibrotic agents might be useful in some but not all patients with chronic LV volume overload. Ninth, several studies have provided proof that ECCM dissolution promotes dilation. 6, 7 An important finding is that a mild reduction of only Ϸ20% in 4-hydroxyproline content is sufficient to reduce the melting temperature of collagen helices below the physiological level of 37°C, thereby decreasing the physical stability of collagen, its resistance to proteolysis, its secretion with the ECCM, and its ability to interact with other matrix components. 7, 40, 44 This implies that lowering collagen below normal might facilitate remodeling and narrow the therapeutic window with collagen-lowering agents after acute MI.
Tenth, the rate of collagen synthesis, at 0.56% per day, is slow compared with 7.2% per day for noncollagen protein, 45 and the 80-to 120-day half-life of collagen is Ϸ10 times longer than that for noncollagen protein. 6 This implies that ECCM replacement after degradation is fairly slow, thus providing a window of potential vulnerability for adverse remodeling in conditions associated with increased ECCM degradation such as acute MI.
ECCM Degradation, ProInflammatory Cytokines, Healing, and Remodeling After MI
Four pathophysiological stages of healing after MI, 7 originally based on data from 194 canine hearts with MI and human hearts 2 and updated from subsequent studies, may be used for timing therapeutic interventions (Table 3) . After acute MI, very early ECCM degradation in the IZ 5,12,37 contributes to infarct expansion, 2, 7 and subsequent degradation in the NIZ contributes to progressive global LV dilation over weeks. 2, 7 MMP/TIMP imbalance, with increased MMPs or decreased TIMPs, or a high MMP/TIMP ratio, favors this adverse remodeling. 30, 33, 34, 37 Increased MMP-2/MMP-9 activity has been implicated in the very early ECCM degradation. 46 Other proteases, such as plasmin, cathepsin G, and cathepsin B, may also be involved. 37 Thus, mice deficient in uPA and MMP-9 show decreased acute rupture after MI. 33 However, in the long term, they also show impaired healing, decreased collagen and angiogenesis, and increased heart failure, implying different time-related effects on IZ and NIZ remodeling. 33 The healing process after MI is intertwined with remodeling and attempts to actively repair the damaged site with a firm IZ scar over weeks or months, depending on the infarct size, healing conditions, and species. 2, 7 Many cell types, including inflammatory cells, myocytes, fibroblasts, and vas- • Anti-TGF-␤; TGF-␤ inhibitors 7
• Interferon-␥ 7
• ACE inhibitors 7, 11, 28 • Parathormone 7, 42 • ARBs 7, 11 • Thyroid hormone 7, 42 • Bradykininase inhibitors 7 • Glucocorticoids 7, 41, 42 • Endothelin antagonists 7, 29 • Steroid hormones 7, 41, 42 • Chymase inhibitors 7 • Vasopeptidase inhibitors • TIMP inhibitors 30, 31 • Bradykinin
Collagen synthesis promoters (1synthesis) • P4H 40, 41 • Growth hormone 7
• TGF-␤ 1 (stimulate myofibroblasts) 11, 17 • Bradykinin inhibitor 7 • Angiotensin II, aldosterone, ACE, chymase, endothelin-1 7,9-11
• CTGF, PDGF, EGF, TGF-␣, bFGF, IGF 41 • Growth hormone 7 • Ascorbic acid (vitamin C) 36, 40 Collagen breakdown inhibitors (2breakdown) • TIMPs 30, 31 • Recombinant TIMP 30, 31 • Phenytoin
42
• Retinoids (vitamin A) 42 • MMP inhibitors 7 EGF, epidermal growth factor; TGF-␣, transforming growth factor-␣; bFGF, basic fibroblast growth factor; IGF, insulin-like growth factor. Other abbreviations as in text.
cular cells, as well as proinflammatory cytokines; growth factors; and endocrine, autocrine, paracrine and intracrine factors, participate in the ECCM and LV remodeling ( Figures  1 and 2) . Inflammatory cells, which are increased in very early and early stages, 2,27 produce MMPs 25 that modulate ECCM remodeling. Mast cells may lead to MMP activation, collagen degradation, and LV dilation. MMP-9, localized to neutrophils early after reperfused MI, 7 mediates ECCM degradation. Proinflammatory cytokines, expressed by cardiomyocytes, fibroblasts, macrophages, and other nucleated cells, orchestrate the inflammatory responses, thereby modulating healing. The expression of proinflammatory cytokines and MMPs has also been colocalized to cardiac fibroblasts, 37 and several cytokines, such as IL-1␤ and TNF-␣, which are elevated in the IZ during early healing and in the NIZ during later stages after MI, activate MMPs and regulate the activity of TIMPs, 7 thereby contributing to LV remodeling. 24 MMPs also regulate cytokine activity. 25 In heart failure, as is often the case after MI, overexpression of proinflammatory cytokines initially results in MMP activation, loss of fibrillar collagen, LV dilation, myocyte loss through apoptosis, and progression of heart failure. 25 However, long-term stimulation by proinflammatory cytokines results in increased TIMPs, decreased MMP/TIMP ratio, and increased fibrillar collagen 25 and induces ongoing diffuse microinflammation, scarring, and long-term remodeling.
Contrary to common belief, the IZ scar is a living, dynamic structure. 47 The fibrogenic cytokine TGF-␤ 1 and the proinflammatory cytokines TNF-␣ and IL-1 25 induce phenotypic remodeling of cardiac fibroblasts into myoFbs. 17 These myoFbs contain ␣-smooth muscle actin and mediate scar contraction. 7, 17 They appear early after MI, mainly in and 
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around the IZ, and persist throughout healing and beyond, having been found in human MI scars for up to 17 years. 7 Endothelin and AngII receptors on the myoFbs and regulatory signals, such as AngII, TGF-␤ 1 , and ACE, modulate MMP activity and ECCM remodeling. 7, 11 MyoFbs not only produce collagen types I and III after MI, but their persistence, together with continued expression of AngII, TGF-␤ 1 , and ACE in later stages, is accompanied by low-grade collagen turnover in mature IZ scars. 7, 47 Remodeling of the IZ and NIZ after MI depends on the 3D organization of the ECCM besides the amount and type of collagen. 6, 7 Increases in the amount of collagen by up to 12-fold in the IZ scar during early and late healing phases, and by 2 to 3-fold in the NIZ during late and very late stages, 27, 28 contribute resistance to distension. 48 Although collagen types I and III in the IZ increase during early healing, the new collagen, being immature and mostly thin type III, remains susceptible to stretch even by 15 weeks. As a result, the infarcted left ventricle is more distensible in the early 2-week window after MI 48 but remains distensible in the later stage. Subsequent collagen maturation, involving development of intermolecular cross links (Figure 2) , loss of water and ground substance, and replacement by type I, results in increased collagen type I/III ratio and greater resistance to distension. Greater increase of cross-link formation in the IZ than NIZ by Ϸ13 weeks contributes tensile strength. The mature IZ scar, apart from being alive, is anisotropic and trilayered and shows a different 3D orientation of each layer. 7 Taken together, the data suggest that ECCM remodeling during healing after MI is an attempt to restore mechanical strength and resistance of both IZ and NIZ of the infarcted ventricle to distension. The importance of the cytokine AngII in fibrosis during tissue repair, the local production of tissue AngII after injury, the presence of AngII receptors on cardiac myocytes and fibroblasts, and their roles in ECCM turnover have been reviewed. 11 Local ACE, which is markedly elevated in high-turnover sites including the IZ, contributes local AngII. 11, 47 AngII stimulation of AT 1 receptors, which are upregulated during healing after MI, 11 induces fibrosis. AngII type 2 (AT 2 ) receptors, which are re-expressed after MI and upregulated in heart failure, are more abundant in human than in rat hearts, are expressed in fibroblastlike cells, and mediate fibrosis, 7, 49 and AT 2 loss prevents collagen deposition and causes cardiac rupture. 38 
Antiremodeling Therapies After MI: Lessons About Timing From Long-term Studies
The aim of antiremodeling therapy after MI is to prevent, limit, or reverse adverse structural remodeling and thereby interrupt the sequence of LV dilation, LV dysfunction, disability, and death. 2 An important aspect of this goal is to protect the ECCM during remodeling after MI. 7 Longitudinal studies suggested that timing and duration of therapy are critical. 2 Sequential changes during LV remodeling after MI (Figure 1 ) span the phases of acute MI, healing, and repair over weeks to months (Figure 2 ) and beyond. 1, 2, 16 Because mechanical deformation forces and increased wall stress act on the IZ and NIZ throughout these phases, thereby promoting progressive LV dilation 1,2,7 and stimulating fibrosis, 6, 7 early and prolonged antiremodeling therapy is favored.
However, several of the antiremodeling strategies currently used after MI exert pleiotropic effects that can potentially affect ECCM turnover in both the IZ and NIZ 7 (Table 2 and Figure 3 ). Thus, ACE-Is, ARBs, and aldosterone blockers decrease ECCM, 7, 11 and the aldosterone antagonist spironolactone decreases collagen turnover. 9 ARBs also decrease P4H. 7 Reperfusion disrupts ECCM, 7 increases MMPs and collagen degradation, 30 decreases IZ collagen, 7, 13 accelerates healing, 7 decreases cross-links, 7 and increases ruptures. 39 Unloading with the LV assist device results in downregulation of MMPs, increased TIMPs, decreased collagen damage, and increased collagen cross-links. 7 ␤-Blockers decrease MMPs. 7 Nitrates preserve IZ collagen and prevent the decrease in collagen after reperfusion. 7 Digitoxin increases P4H activity, although digoxin does not alter IZ collagen. 7 Endothelins increase collagen synthesis and decrease MMPs, 7 whereas endothelin blockade impairs healing after MI. 29 Bradykinin increases MMPs and decreases collagen. 7 Agents such as adenosine, which elevate cAMP, NO, and cGMP, decrease fibrosis. 7 Several studies suggested potentially harmful effects with some therapies after MI, 7,13,28,50 -52 supporting caveats against hypotension with vasodilators very early after MI, 50 or impairing healing with powerful anti-inflammatory drugs during early healing. 51 Other post-MI studies demonstrated progressive LV enlargement over 1 year 7, 16 or 3 years 52 despite therapy, and morbidity and mortality remain high. 53 In addition, cardiac rupture remains a major cause of death after reperfused MI, 7, 39 and the number of post-MI patients needing the LV assist device or awaiting transplantation is increasing, suggesting that protection against LV dilation, adverse ECCM remodeling, decreasing IZ collagen, and impairing healing is needed.
Caveat With the Use of Antifibrotic Agents
After MI
A major aim of antifibrotic therapy is to inhibit or reverse cardiac fibrosis and its adverse effects on LV function. 7 Potential approaches include long-term suppression of ACE, TGF-␤ and CTGF, P4H, and MMPs; inhibition of TGF-␤-stimulated collagen synthesis and profibrotic cytokines with pirfenidone; PDGF inhibition and enhancement of adenosine with pentoxifilline; and breaking excessive cross-links due to advanced glycation end products by 4,5-dimethylthiazolium chloride (ALT-711). 7 Although MMP inhibitors may reduce MMP activation acutely, they may reduce ECCM in the long term. Antifibrotic therapy may be beneficial for noninfarcted hearts with chronic LV pressure overload 6, 7 and possibly for ischemic cardiomyopathy and the NIZ after remote MI. However, caution might be advisable in idiopathic dilated cardiomyopathy without MI because of increased MMPs, decreased TIMPs, and reduced cross linking. 6 Collective evidence emerging from experimental and clinical studies using antiremodeling strategies after MI suggest that careful attention should also be given to timing (Figure 2 ), especially because antifibrotic agents exert global actions that can affect both the IZ and NIZ (Figure 3 ). Experimental data on the temporal evolution of healing and ECCM remodeling 2, 3, 7 suggest that these agents could potentially enhance adverse ECCM remodeling in the IZ during the highly vulnerable periods of very early and early stages of healing after MI ( Figure 3 ; Table 3 ). Pending further safety data, it might also be prudent to exercise caution during the phase beyond scar formation.
Protecting the ECCM of the IZ After MI
Although the importance of ECCM remodeling in paradigm 1 is widely acknowledged, 1-7,12,24 -30 little has been done to protect the ECCM in the IZ. Although growth hormone was shown to stimulate post-MI repair, increase IZ scar collagen, and reduce LV aneurysm formation, 7 such approaches have not been actively pursued. Strategies to protect the ECCM after MI, especially in the IZ, might further lower post-MI mortality and limit morbidity. Several factors, as shown in Figure 3 , could be targeted. 7 In contrast to global approaches that target both the IZ and the NIZ with systemic delivery of adjunctive agents, regional strategies could be applied to selectively protect the IZ against adverse ECCM remodeling. Monitoring using several markers could be systematically applied to detect potentially adverse ECCM and LV remodeling after MI during therapy. 7 
Summary
Prevention of adverse remodeling after MI remains a therapeutic challenge. Current antiremodeling therapy is clearly not ideal, as many ventricles continue to enlarge after MI, and mortality and morbidity remain significant despite therapy. Collective evidence indicates that the ECCM plays a major role in healing and remodeling after MI. 6, 8 Antifibrotic agents targeting excessive ECCM might be beneficial in selected patients without MI. After MI, however, the situation is complicated by the development of an IZ and a NIZ with differential pathophysiological responses. Because one aim of therapy is to maximize benefits and minimize unwanted, often delayed adverse effects, failure to address protection of the ECCM in the IZ as well as the NIZ in the long term seems to deal with only half the problem. Protecting the ECCM in post-MI survivors should be a future priority.
